Organ Transplant MedTech TransMedics Q3 Performance Disappoints, Analyst Outlines Investor Worries
Portfolio Pulse from Vandana Singh
TransMedics Group Inc (NASDAQ:TMDX) reported disappointing Q3 results, missing EPS and sales expectations. Despite a 64% sales increase, the stock fell 30.6% due to missed targets and lowered analyst price targets. Analysts maintain positive ratings but adjust price targets downward.
October 29, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
TransMedics reported Q3 EPS of $0.12, missing the $0.30 consensus, and sales of $108.8M, below the $115M consensus. Despite a 64% sales increase, the stock fell 30.6% due to missed targets and lowered analyst price targets.
The significant drop in TMDX stock price is due to the company's failure to meet EPS and sales expectations, which is compounded by analysts lowering their price targets. Despite positive long-term growth potential, the short-term outlook is negative.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100